1. Clinical Need
Biofilm infections on indwelling medical devices constitute one of the largest unsolved problems in hospital infection control. Bacterial biofilms form on approximately 80% of device surfaces exposed to biological fluids, creating structured microbial communities encased in a self-produced extracellular polymeric substance (EPS) matrix. Once mature, biofilm-resident bacteria exhibit 100- to 1,000-fold increased tolerance to antibiotics compared to planktonic cells (Costerton JW et al., “Bacterial Biofilms: A Common Cause of Persistent Infections,” Science, 284(5418), 1318–1322, 1999). The standard clinical response to an established device biofilm is removal of the device, frequently requiring invasive surgery.
The Centers for Disease Control and Prevention (CDC) estimates 687,000 healthcare-associated infections (HAIs) occur annually in US acute care hospitals, causing 72,000 to 90,000 deaths per year. Catheter-associated urinary tract infections (CAUTIs) represent the most common device-related HAI, affecting approximately 450,000 patients annually in the United States. Central line-associated bloodstream infections (CLABSIs) affect approximately 41,000 patients per year. Periprosthetic joint infections (PJIs) affect 30,000 to 70,000 patients annually, with two-stage revision surgery costing $50,000 to $100,000 per case.
The Agency for Healthcare Research and Quality (AHRQ) estimates direct medical costs for HAIs at $28.4 to $45 billion annually in the United States. Since 2008, the Centers for Medicare and Medicaid Services (CMS) has classified CAUTIs as “hospital-acquired conditions” and no longer provides additional reimbursement for CAUTI treatment costs, transferring the full financial burden to hospitals. This policy creates acute institutional demand for technologies that either prevent or actively treat device biofilms.
Existing prevention technologies are exclusively passive: silver alloy or chlorhexidine antimicrobial coatings that degrade over days, antibiotic-impregnated surfaces that contribute to resistance development, and antimicrobial lock solutions for catheters that cannot reach established biofilm within the device wall or surrounding tissue. A 2022 Cochrane systematic review found inconsistent evidence that silver-coated catheters reduce symptomatic CAUTI, particularly in long-term catheterization beyond 14 days. No commercially available technology provides active, controllable, on-demand biofilm destruction on an indwelling device without removing the device.
2. State of the Art
Three independent research paradigms for active microrobotic biofilm eradication have emerged since 2019, each validated in progressively more clinically relevant models by groups on three continents. The field is characterized by rapid convergence: all three approaches use magnetic actuation as the primary locomotion mechanism and combine mechanical biofilm disruption with chemical bacterial killing.
Catalytic nanoparticle assemblies (University of Pennsylvania)
The laboratory of Hyun (Michel) Koo and Edward Steager at the University of Pennsylvania pioneered the use of FDA-approved iron oxide nanoparticles with dual catalytic and magnetic functionality. Their catalytic antimicrobial robots (CARs) exploit Fenton chemistry: iron oxide catalyzes hydrogen peroxide decomposition into hydroxyl radicals that kill bacteria and degrade the EPS matrix, while the same nanoparticles assemble into magnetically controllable robotic formations that physically remove biofilm debris. Published applications span dental biofilm on natural teeth and 3D-printed tooth models (Hwang et al., Science Robotics, 2019), root canal biofilm in complex endodontic geometry (Babeer et al., Journal of Dental Research, 2022), and tympanostomy tube biofilm (ex vivo human cadaver ear model, CUHK collaboration). The Penn group holds US Patent 12,433,295 (granted October 2025) covering iron oxide nanoparticle robot systems for biofilm eradication, and the Penn Center for Innovation is actively seeking commercial partners.
Viscoelastic hydrogel robots (Chinese University of Hong Kong)
Li Zhang’s Multi-Scale Medical Robotics Center at CUHK developed liquid-bodied antibiofilm robots composed of polyvinyl alcohol (PVA) hydrogel embedded with neodymium iron boron (NdFeB) microparticles (5 μm average diameter, 20 wt%). The robots exploit switchable viscoelastic behavior: under gradient magnetic fields, the robot translates as a solid body, while under rotating fields, it deforms to conform to complex surface topographies including mesh weave patterns, stent struts, and irregular tissue surfaces. This conformability allows the robot to access biofilm in geometric niches that rigid robots cannot reach. The group has published in Science Advances (2025, biofilm on hernia mesh and biliary stents with in vivo mouse validation) and Science Robotics (2025, photocatalytic microrobots for sinus biofilm in a rabbit model). Both studies include animal models with quantitative efficacy and safety endpoints.
Magnetic soft robots for catheter applications (ITMO University)
Baburova et al. at ITMO University designed magnetic soft robots specifically dimensioned for the geometric constraints of urethral catheter lumens. They systematically fabricated and compared seven robot geometries, identifying the octagram design as optimal for biofilm eradication in tubular environments. The optimized robot achieved 100% biofilm eradication at 2.88 ± 0.6 mm/s traversal velocity (ACS Nano, 2023). This shape-optimization approach demonstrates that robot geometry is a tunable design parameter with measurable impact on eradication efficacy, relevant for any geometry-specific application (catheter lumens, stent interiors, tympanostomy tube channels).
Swarming microrobots (Nanorobots Research Center, Czech Republic)
Martin Pumera’s group developed swarming magnetic photoactive microrobots composed of Fe3O4/BiVO4 that combine ferromagnetic propulsion under rotating magnetic fields with photocatalytic reactive oxygen species (ROS) generation under visible light. The dual-mechanism approach (mechanical disruption via coordinated swarming plus chemical killing via ROS) was validated on titanium dental implant surfaces (ACS Nano, 2022). Follow-on work demonstrated virus-conjugated microrobots for enhanced specificity (Advanced Materials, 2026).
All four groups share a critical limitation: navigation is controlled by manually operated external magnetic fields with no autonomous feedback control. No published system integrates real-time imaging analysis with closed-loop magnetic actuation via AI. This gap, the absence of autonomous navigation, is the primary barrier between laboratory demonstration and clinical deployment.
3. Foundational Research
Hwang G, Paula AJ, Hunter EE, Liu Y, Babeer A, Karabucak B, Stebe K, Kumar V, Steager E, Koo H (2019). “Catalytic antimicrobial robots for biofilm eradication.” Science Robotics, 4(29), eaaw2388. DOI: 10.1126/scirobotics.aaw2388.
The Penn team designed two classes of catalytic antimicrobial robots using iron oxide nanoparticles approved by the FDA for human parenteral administration (ferumoxytol). In the first configuration, nanoparticles suspended in H2O2 solution generated bactericidal hydroxyl radicals via Fenton chemistry while being magnetically assembled into surface-adapted robotic formations for debris removal. In the second configuration, nanoparticles were embedded in moldable 3D-printed helical soft robots for navigation through confined spaces. Testing on 3D-printed replicas of human teeth and on extracted human teeth demonstrated complete biofilm biomass removal and bacterial killing. In a rat oral model, robotic treatment produced no detectable gingival tissue damage. This paper established the foundational proof-of-concept for iron oxide catalytic antimicrobial robots and demonstrated that FDA-approved materials can serve as the primary robotic component, simplifying the future regulatory pathway.
Sun B, Guo J, Hao B, Cao Y, Chan TKF, Sun M, Sung JJY, Zhang L (2025). “Liquid-bodied antibiofilm robot with switchable viscoelastic response for biofilm eradication on complex surface topographies.” Science Advances, 11(11). DOI: 10.1126/sciadv.adt8213.
The CUHK team fabricated robots from PVA hydrogel dynamically cross-linked with boronic ester bonds, embedded with NdFeB microparticles (5 μm diameter, 20 wt%), and loaded with levofloxacin (250 μg/g). The boronic ester cross-links provide switchable viscoelasticity: the robot behaves as a solid under low-frequency magnetic actuation and flows as a viscous liquid under high-frequency rotating fields, conforming to surface topographies. Against MRSA biofilm (ATCC 43300), the levofloxacin-loaded robot achieved 97.73% viable cell reduction in vitro and 84.25% biomass reduction on surgical hernia mesh (Bard Mesh Pre-Shaped 0113700), with zero detectable living colonies on treated mesh versus approximately 3 × 103 CFU on controls. On metallic biliary stents in an ex vivo porcine bile duct model, the robot removed 81.82% of living cells. In the in vivo BALB/c mouse model (n = 7 treatment, n = 8 control), the robot reduced bacterial colonies on implanted infected nitinol stents by 93.45% (P < 0.0001), normalized white blood cell counts (5.20 ± 1.59 vs. 9.79 ± 4.43 × 109/mL by day 10), and restored body weight to 100.20 ± 4.86% of baseline versus 94.67 ± 6.11% in controls by day 12. This paper provides the strongest in vivo evidence to date for microrobotic biofilm eradication on an implanted medical device, demonstrating both efficacy and systemic safety endpoints.
Mayorga-Martinez CC, Zelenka J, Klima K, Mayorga-Burrezo P, Hoang L, Ruml T, Pumera M (2022). “Swarming Magnetic Photoactive Microrobots for Dental Implant Biofilm Eradication.” ACS Nano, 16(6), 8694–8703. DOI: 10.1021/acsnano.2c02516.
Pumera’s group fabricated swarming microrobots from Fe3O4/BiVO4 assembled via polyethylenimine micelles. Fe3O4 provides ferromagnetic propulsion under transversal rotating magnetic fields; BiVO4 generates reactive oxygen species under visible light irradiation. The dual-mechanism approach (mechanical disruption via coordinated swarm locomotion plus photocatalytic bacterial killing) achieved efficient biofilm eradication on titanium dental implant surfaces. The swarming behavior is significant because coordinated multi-robot action improves surface coverage compared to single-robot operation, particularly on irregular implant topographies with undercuts and threaded regions that single robots cannot fully access.
Baburova PI, Kladko DV, Lokteva A, Pozhitkova A, et al. (2023). “Magnetic Soft Robot for Minimally Invasive Urethral Catheter Biofilm Eradication.” ACS Nano. DOI: 10.1021/acsnano.2c10127. PMID: 37871301.
The ITMO University team fabricated seven distinct magnetic soft robot geometries (star, cross, octagram, circle, triangle, square, hexagon) and systematically compared their biofilm eradication performance in a 20 Fr (5.1 mm inner diameter) urethral catheter model. The optimized octagram design achieved 100% biofilm eradication at a velocity of 2.88 ± 0.6 mm/s under 15 Hz rotation at 10 mT field strength. This represents the only published complete eradication result (0% residual biofilm) under controlled conditions. The systematic geometry comparison demonstrates that robot shape is a tunable design parameter with measurable impact on efficacy in tubular geometries, which is directly relevant to catheter lumen applications representing the highest-volume device biofilm market.
Yu H, Liu X, Zhang Y, Shen J, et al. (2025). “Photocatalytic microrobots for treating bacterial infections deep within sinuses.” Science Robotics, 10(103), eadt0720. DOI: 10.1126/scirobotics.adt0720. PMID: 40561042.
The CUHK/Shenzhen University team demonstrated copper single-atom-doped bismuth oxoiodide (Cu-BiOI) microrobots (approximately 3 μm diameter) delivered via magnetically guided optical fiber into rabbit sinus cavities under real-time x-ray visualization. Photothermal activation reduced pus viscosity on inflamed mucosal tissues, enhancing microrobot swarm penetration by more than threefold compared to unactivated controls. In vivo validation in the rabbit sinusitis model confirmed biofilm disintegration, healthy tissue restoration, reduced inflammation, minimized fibrosis, and no detectable mucosal damage. This paper extends the microrobotic biofilm eradication paradigm from device surfaces to anatomical cavity infections, demonstrating clinical potential beyond indwelling device applications and validating the combination of real-time imaging guidance with magnetic actuation in a living animal model.
Tran HH, Watkins A, Oh MJ, Babeer A, Schaer TP, Steager E, Koo H (2024). “Targeting biofilm infections in humans using small scale robotics.” Trends in Biotechnology. DOI: 10.1016/j.tibtech.2023.10.004. PMID: 37968157.
This comprehensive translational review from the Penn group surveys the trajectory of microrobotic biofilm eradication from proof-of-concept to clinical translation. The authors identify the field as “rapidly moving from proof-of-concept to translational biomedical applications using ex vivo, animal, and clinical models.” Clinical targets discussed include dental biofilms, root canal infections, tympanostomy tubes, biliary stents, titanium orthopedic and dental implants, and catheter surfaces. The review provides a roadmap for translational milestones and identifies manufacturing scalability and autonomous navigation as the two primary barriers to clinical deployment. This assessment from the originators of the field validates both the clinical trajectory and the specific technical gaps that HHA proposes to address.
4. Competitive Landscape
No company currently commercializes magnetically actuated microrobots for active biofilm destruction on medical devices. The competitive landscape consists entirely of passive prevention technologies and adjacent (non-biofilm) microrobotic platforms.
Passive device coatings (Teleflex, BD/Bard, Medline) represent the existing standard of care: silver alloy coatings, chlorhexidine-impregnated surfaces, and antibiotic lock solutions. These technologies prevent initial colonization but cannot address established biofilms and degrade over time, particularly in long-term catheterization beyond 14 days. The market for antimicrobial catheter coatings exceeds $1.3 billion annually but is fundamentally limited to prevention rather than treatment.
Adjacent microrobotic platforms include Robeaute ($28M Series B, January 2025, magnetically guided microrobots for neurosurgery), Microbot Medical (NASDAQ: MBOT, endoluminal robots for vascular applications), and Artedrone (raising EUR 20M Series B, microrobots for thrombectomy). None of these companies conduct biofilm-related research or have published biofilm eradication data.
The absence of commercial entrants reflects the interdisciplinary barrier: the technology requires expertise in magnetic microrobotics, biofilm microbiology, medical device manufacturing, and AI-based navigation control. Academic laboratories publish the science but lack manufacturing capability. Medical device companies optimize within existing platform architectures. The result is a validated technology with no commercial champion.
5. Addressable Scope
Bottom-up calculation
- CAUTI: 450,000 episodes/year (US, CDC) × $3,500 average addressable revenue per robotic treatment = $1.575B
- CLABSI: 41,000 episodes/year (US, CDC) × $10,000 average addressable revenue = $410M
- Periprosthetic joint infection: 50,000 episodes/year (US) × $20,000 addressable revenue (alternative to $50K–$100K revision surgery) = $1.0B
- Total bottom-up US addressable market: approximately $2.98B annually
Top-down cross-check
The global CAUTI prevention urology products market was valued at $3.43 billion in 2025, projected to reach $5.9 billion by 2033 at approximately 7% CAGR (Grand View Research, 2025). The broader biofilm treatment market was valued at $2.39 billion in 2024, projected to reach $4.55 billion by 2032 at 8.39% CAGR (Coherent Market Insights, 2024). The total US economic burden of HAIs is $28.4 to $45 billion annually (AHRQ/CDC). The bottom-up estimate of $2.98B falls within the range bounded by these adjacent market segments. The estimate is conservative: it excludes dental implants, biliary stents, hernia mesh, tympanostomy tubes, and all international markets.
Reimbursement pathway
No existing CPT code covers microrobotic biofilm intervention. Adjacent procedural codes provide a pricing framework: CPT 52310–52318 (cystourethroscopy with catheter manipulation, $600–$2,400 physician reimbursement), CPT 43264 (ERCP with biliary stent exchange, $1,200–$3,500). Initial commercialization would require a Category III CPT code (temporary tracking code for emerging technology), with progression to Category I after clinical adoption data collection. CMS non-reimbursement for hospital-acquired CAUTIs creates institutional incentive to invest in prevention and treatment technologies. Under value-based purchasing, every prevented CAUTI represents direct cost avoidance for the hospital, aligning institutional purchasing incentives with technology adoption.
6. Research Gaps and HHA Contribution
The cited research groups have validated the biofilm eradication mechanism across multiple device types, bacterial species, and animal models. Three specific gaps separate their published results from a deployable clinical system. Each gap maps to a specific HHA team capability.
Gap 1: Autonomous AI-driven navigation
What is missing: Every published prototype relies on manual magnetic field manipulation by an operator watching imaging feedback. No system integrates computer vision analysis of real-time endoscopic or fluoroscopic imaging with a closed-loop controller that autonomously drives the microrobot to biofilm locations. This manual control paradigm is acceptable for laboratory demonstrations on small tissue samples but is impractical for clinical procedures requiring navigation through complex, patient-specific anatomical geometry (catheter lumens, bile ducts, joint capsules).
Why the originating labs have not closed this gap: The Koo/Steager group (Penn) specializes in biofilm microbiology and iron oxide catalysis. The Zhang group (CUHK) specializes in soft robotics and materials science. The Pumera group specializes in nanomaterial chemistry. None of these groups have deep reinforcement learning or computer vision expertise. Their graduate students and postdocs are trained in materials science, chemistry, and mechanical engineering. Building an RL-based navigation controller requires a different skill set: state/action/reward formulation for magnetic actuation, real-time image segmentation for biofilm detection, path planning under deformable anatomy constraints, and safety-bounded control policies that prevent tissue contact injury.
HHA contribution: Haedar Hadi (Lead PI) brings ML model development, evaluation methodology, and scalable compute infrastructure. The navigation controller is a reinforcement learning problem: the state space is the current endoscopic/fluoroscopic image plus robot position, the action space is the magnetic field vector (direction and gradient), and the reward signal is biofilm coverage reduction measured by imaging. Pre-training in simulation (computational models of catheter/stent geometry with synthetic biofilm) followed by fine-tuning on cadaveric tissue provides the sim-to-real transfer pathway.
Gap 2: Manufacturing at clinical grade
What is missing: Current prototypes are hand-fabricated one at a time in research laboratories. The PVA hydrogel robots (Sun et al., 2025) require controlled cross-linking density (boronic ester bond formation is sensitive to pH and temperature), uniform NdFeB microparticle distribution within the hydrogel matrix, and precise drug loading at 250 μg/g concentration with batch-to-batch consistency. None of these processes have been validated under Good Manufacturing Practice (GMP) conditions. Similarly, the iron oxide nanoparticle formulations (Hwang et al., 2019) use FDA-approved materials but require process validation for reproducible catalytic activity across manufacturing batches.
Why the originating labs have not closed this gap: Academic laboratories have no incentive, infrastructure, or expertise for manufacturing scale-up. University reward structures (publications, grants, tenure) do not value manufacturing process development. When a PI publishes a Science Robotics paper, they move to the next publication, not to GMP validation. The manufacturing gap is not a research question; it is an engineering and quality systems challenge that academic environments are structurally unable to address.
HHA contribution: Ahmed (Director of Manufacturing) brings Design for Manufacturability (DFM), production scaling, quality systems (ISO 13485), and process optimization. His contribution begins at month 1 of the research program, not after prototyping is complete. This means: tolerance analysis of hydrogel cross-linking parameters to define manufacturing process windows, particle distribution uniformity testing using standard industrial metrology, drug loading precision validation through statistical process control, and mold/fixture design for batch production of standardized robot geometries.
Gap 3: Clinical translation and regulatory science
What is missing: No first-in-human feasibility study has been conducted. Large animal model validation (porcine biliary or urinary tract, which more closely approximates human device dimensions and anatomy than murine models) is incomplete. The regulatory pathway is undefined: microrobotic biofilm eradication does not fit cleanly into existing FDA device classifications, and no pre-submission meeting has been conducted to establish the regulatory framework. Drug-loaded robots may qualify as combination products requiring coordinated CDRH/CDER review.
Why the originating labs have not closed this gap: Regulatory science is not an academic discipline. PIs at Penn, CUHK, and Czech Academy of Sciences have no internal regulatory affairs capability. Clinical trial design, IND/IDE filing, and FDA pre-submission engagement require dedicated expertise that sits outside the academic reward structure.
HHA contribution: Hass Dhia (Co-PI) brings MS Biomedical Sciences with medical school anatomy training, providing the clinical problem framing (which device types, which patient populations, which anatomical access routes yield the fastest path to clinical validation) and experimental design for animal model studies. His AI infrastructure expertise maps to the system architecture for the integrated navigation/actuation platform. Critically, the HHA approach includes regulatory engagement from month 1: pre-submission meeting with FDA to establish the classification framework before committing resources to a specific device architecture.
Why this matters for funders: Most research proposals end at “it works in the lab.” This proposal includes explicit DFM milestones at every phase, ensuring that prototype decisions consider production scaling, tolerance analysis, and quality systems from day one. This addresses the valley of death between TRL 4–5 prototypes and TRL 7+ deployable systems, the gap where most funded research stalls. The lab-to-production bridge is not an afterthought; it is a parallel workstream with its own deliverables and go/no-go criteria at every milestone.
7. Comparable Funded Projects
Multiple government agencies and programs have committed significant funding to antimicrobial and microrobotic technologies, validating both the technical approach and sustained funder interest in this problem space.
| Source | PI / Entity | Amount | Focus |
|---|---|---|---|
| NIH/NIDCR R01 | H. Koo, UPenn | R01 DE025848 | Catalytic nanoparticle robots for dental biofilm eradication. Produced the foundational Science Robotics (2019) publication and US Patent 12,433,295. |
| NIH/NIDCR R56 | E. Steager, UPenn | R56 DE029985 | Microrobotics platform development for precision biofilm diagnostics and treatment in endodontic applications. |
| ARPA-H PROTECT | Multiple performers | $22.7M (2024) | Synbiotic platform for infection prevention and microbiota restoration. Third ARPA-H antimicrobial resistance investment; total AMR commitment exceeds $150M including DARTS and TARGET programs. |
| Hong Kong InnoHK | L. Zhang, CUHK | Multi-year center | Multi-Scale Medical Robotics Center. Produced Science Advances (2025) and Science Robotics (2025) antibiofilm robot publications. |
| Czech Republic EXPRO | M. Pumera, UCT Prague | 25-15484X | Nanorobots Research Center funding. Produced ACS Nano (2022) swarming microrobot and Advanced Materials (2026) virus-enhanced microrobot publications. |
The convergence of funding from NIH, ARPA-H, Hong Kong InnoHK, and European research councils confirms that multiple independent funding bodies consider microrobotic biofilm eradication a viable and sustained research direction. ARPA-H’s $150M+ commitment to antimicrobial resistance programs since 2023 signals that the US government considers this problem space a strategic health security priority, creating a receptive funding environment for proposals that address device-associated biofilm infections specifically.
8. Opportunity Assessment
TRL assessment: 4 (component validation in relevant environment)
The evidence chain: in vitro validation on clinical-grade devices (hernia mesh, biliary stents, urethral catheters, dental implants, titanium surfaces) is complete across four independent groups. Ex vivo validation on porcine bile duct tissue is complete (Sun et al., 2025). In vivo validation in murine (BALB/c mouse, n = 15, CUHK) and rabbit (sinusitis model, CUHK/Shenzhen) models demonstrates statistically significant biofilm reduction (93.45%, P < 0.0001) with no adverse tissue effects and normalized inflammatory markers. No first-in-human trial has been conducted. TRL advancement to 5 requires: (a) large animal model validation in porcine biliary or urinary tract, (b) 90-day chronic biocompatibility study, and (c) first-in-human feasibility study under Investigational Device Exemption (IDE).
Technical risks
Magnetic field attenuation at clinical depth
ModerateThe Sun et al. (2025) system operates at 10.7 to 28.4 mT with actuation distances of 25 to 50 mm. Deep abdominal implants (e.g., biliary stents, joint prostheses) may require actuation at 100+ mm depth where field gradients attenuate significantly.
Mitigation: Stereotaxis clinical magnetic navigation systems achieve sufficient field gradients at 100+ mm depth for cardiac catheter guidance, with over 500 installations globally. Halbach array and superconducting magnet designs further extend operational range. The physics of deep-tissue magnetic actuation is solved; the engineering integration for biofilm-specific applications requires adaptation, not invention.
Robot retention or fragmentation in vivo
ModerateDetached robot fragments could cause embolic or obstructive complications if not fully retrieved or degraded post-procedure.
Mitigation: PVA hydrogel robots are fully biodegradable: complete degradation within 30 minutes at low cross-linking density (Sun et al., 2025). Iron oxide nanoparticles are FDA-approved for intravenous administration (ferumoxytol, Feraheme) and are metabolized via normal iron recycling pathways. Robot composition can be tuned for guaranteed post-procedural degradation, converting the retention risk into a controlled biodegradation timeline verified by imaging.
Adaptive algorithm regulatory classification
ModerateIf the navigation algorithm adapts to patient-specific anatomy in real time (continuous on-device learning), it qualifies as an adaptive AI/ML medical device under FDA’s 2023 guidance framework, requiring a Predetermined Change Control Plan (PCCP) that specifies the bounds and conditions under which the algorithm may update.
Mitigation: Initial commercialization should use a locked algorithm trained on a comprehensive anatomical atlas of catheter, stent, and implant geometries using simulation and cadaver data. A locked-after-training algorithm follows the standard De Novo classification pathway. Adaptive on-device learning can be introduced in a second-generation device under a PCCP framework after the locked-algorithm device establishes regulatory precedent. This staged approach (locked first, adaptive second) reduces regulatory risk for initial market entry while preserving a roadmap for algorithm improvement. Regulatory precedents for this staged approach include NeuroPace RNS System (initially locked parameters, later enabled physician-adjustable adaptive settings).
Regulatory pathway
No predicate device exists for active microrobotic biofilm destruction, making De Novo classification the most probable pathway. Relevant regulatory precedents include: NeuroPace RNS System (PMA, first closed-loop autonomous neural stimulation device, demonstrating FDA willingness to approve autonomous implantable devices with adaptive algorithms), Stereotaxis Epoch Solution (510(k), clinical magnetic navigation system for cardiac catheterization, demonstrating FDA comfort with magnetic actuation in vascular environments), and SetPoint Medical VNS (PMA, vagus nerve stimulation for rheumatoid arthritis, demonstrating FDA pathway for bioelectronic devices treating non-neurological conditions). Drug-loaded robots (levofloxacin, indolicidin) may qualify as combination products requiring CDRH lead with CDER consultation. Estimated regulatory timeline: 2 to 3 years from IDE filing to De Novo authorization. Regulatory approval creates a competitive moat: the combination of clinical trial data, manufacturing validation, and De Novo classification defines the predicate for all subsequent entrants, establishing a 3- to 5-year barrier to competitor entry.
Proposed experimental approach (first 6 months)
Month 1–2: Replicate Sun et al. (2025) PVA hydrogel robot fabrication; establish in-house synthesis with manufacturing process characterization (Ahmed). Simultaneously initiate RL environment design for catheter lumen navigation in simulation (Haedar). Month 3–4: Validate robot performance on commercial catheter and stent samples in vitro; begin systematic shape optimization for catheter lumen geometry following Baburova et al. (2023) methodology. Month 5–6: Integrate real-time endoscopic imaging with magnetic actuation controller in a benchtop flow phantom mimicking catheter-in-bladder geometry; establish baseline autonomous navigation performance metrics. Go/no-go at month 6: autonomous navigation achieves ≥80% biofilm surface coverage in phantom model within 5 minutes, with zero tissue-contact events.
9. Team Capabilities
Hass Dhia
MS Biomedical Sciences (Wayne State University School of Medicine). Medical school anatomy training (anatomy TA) provides direct domain knowledge for this opportunity: biofilm microbiology, device-tissue interface biology, and the anatomical geometry of target device locations (urinary tract, biliary tree, joint capsules). AI infrastructure architect with experience designing multi-agent orchestration systems. Maps to: clinical problem identification and anatomical framing (which device types and patient populations yield the fastest regulatory path), experimental design for animal model studies (species selection, endpoint definition, statistical powering), and system architecture for the integrated navigation/actuation control platform. Responsible for FDA pre-submission strategy and regulatory science coordination.
Haedar Hadi
MS Computer Science (Boston University, Information Systems focus). Cloud and database architecture, ML model development, evaluation methodology, benchmark design, and scalable compute infrastructure. Maps to: reinforcement learning controller design for autonomous magnetic navigation (state/action/reward formulation, sim-to-real transfer from computational anatomy models to physical phantoms and tissue), computer vision pipeline for real-time biofilm detection under endoscopic imaging (segmentation, localization, coverage estimation), evaluation framework design (standardized benchmarks for navigation precision, eradication completeness, and safety metrics), and scalable training infrastructure for RL policy optimization across diverse anatomical geometries.
Ahmed
Director of Manufacturing. Design for Manufacturability (DFM), production scaling, quality systems (ISO 13485), and process optimization. Maps to: hydrogel robot fabrication process development (cross-linking parameter windows, particle distribution uniformity, drug loading precision via statistical process control), magnetic actuation hardware design for clinical deployment (compact, sterilizable, compatible with existing procedural suites), mold and fixture design for batch production of standardized robot geometries, and tolerance analysis ensuring batch-to-batch consistency in magnetic response, degradation kinetics, and drug release profiles.
The lab-to-production bridge. Most research proposals end at “it works in the lab.” This proposal includes explicit DFM milestones at every phase, ensuring that prototype decisions consider production scaling, tolerance analysis, and quality systems from day one. Ahmed’s manufacturing contribution begins at month 1, not after prototyping is complete. This addresses the valley of death between TRL 4–5 prototypes and TRL 7+ deployable systems: the gap where most funded research stalls because the team that built the prototype has no manufacturing expertise, and the manufacturing partner brought in later discovers that the prototype was never designed for production. This proposal prevents that failure mode by design.
The team composition addresses a specific structural gap in the field. The four leading academic groups (Penn, CUHK, ITMO, Czech Academy) have deep materials science, chemistry, and mechanical engineering expertise but lack: (a) reinforcement learning and computer vision capability for autonomous navigation, (b) manufacturing engineering for clinical-grade production, and (c) regulatory science for FDA pathway navigation. HHA provides precisely these three capabilities. The team is positioned as a computational/manufacturing bridge between academic science and clinical deployment, not as a competitor attempting to outperform $500M-funded incumbent device companies in their core competency of passive antimicrobial coatings.
10. Recommended Next Steps
Target funder programs
- NIH/NIBIB R21 (Exploratory/Developmental): “Biomedical Technology Development and Innovation” study section. R21 awards provide $275,000 over 2 years for proof-of-concept studies. Target: autonomous navigation controller validation on benchtop phantoms.
- NIH/NIDCR R01: Building on the NIDCR-funded foundational work (R01 DE025848), propose expansion from dental biofilm to catheter/stent applications with AI navigation. R01 awards provide $250,000–$500,000 per year for 3–5 years.
- ARPA-H Open BAA: Align with ARPA-H’s $150M+ antimicrobial resistance investment thesis. Propose microrobotic biofilm eradication as an active treatment modality complementing the PROTECT (prevention), DARTS (diagnostics), and TARGET (drug development) programs. ARPA-H awards range from $1M to $50M.
- NSF CBET SBIR Phase I: “Biomedical Engineering” topic. Phase I provides $275,000 for 12 months. Target: manufacturing process feasibility for standardized microrobot production.
- VA Rehabilitation Research & Development: PJI is a significant burden in the veteran population due to high rates of orthopedic implant surgery. VA RR&D SPiRE awards provide $50,000 for 1 year of pilot data generation.
Estimated funding range
Based on comparable awards in the microrobotics and antimicrobial device spaces, a phased funding strategy targets $275K (R21 or SBIR Phase I, 12–24 months) for initial navigation controller validation and manufacturing feasibility, followed by $1.5–3M (R01 or ARPA-H, 3–5 years) for large animal validation and pre-clinical regulatory package.
Proposed 24-month milestone timeline
- M1–3 R&D: Replicate PVA hydrogel robot fabrication in-house; establish baseline eradication performance on commercial catheters and stents. Manufacturing: Process characterization of cross-linking, particle distribution, and drug loading. Define manufacturing process windows. Regulatory: Submit FDA Pre-Sub request for De Novo classification guidance.
- M4–6 R&D: Build RL navigation controller in simulation; validate on benchtop flow phantom with endoscopic imaging feedback. Go/no-go: ≥80% biofilm coverage in phantom within 5 min, zero tissue contacts. Manufacturing: First batch production run (n = 50 robots); measure batch consistency metrics.
- M7–12 R&D: Cadaveric tissue validation of navigation controller in human urinary tract and biliary anatomy. Systematic biofilm eradication testing (3 bacterial species, 3 device types, n = 10 per condition). Manufacturing: Scale to n = 200 batch with statistical process control. Regulatory: Incorporate FDA Pre-Sub feedback into device design; initiate ISO 10993 biocompatibility testing.
- M13–18 R&D: Porcine model validation (biliary stent biofilm eradication, n = 12 per arm). Primary endpoint: ≥90% bacterial reduction vs. untreated control. Secondary endpoints: tissue histopathology, inflammatory markers, robot material clearance. Manufacturing: GMP-aligned pilot production line (n = 500 batch). Regulatory: Complete biocompatibility, sterility, and shelf-life testing.
- M19–24 R&D: Compile pre-clinical data package. Prepare IDE application for first-in-human feasibility study. Manufacturing: Design transfer documentation; validate production process for clinical trial supply. Regulatory: Submit IDE application. Target: IDE approval by month 24, first-in-human enrollment by month 26.